Skip to main content
SpringerLink
Log in

Hepatitis C Virus: Epidemiology and Clinical Features of Related Cancer

  • Chapter
  • First Online:
Viruses and Human Cancer

  • 1004 Accesses

Abstract

Hepatitis C virus (HCV) affects about 3 % of the world population. The region with the highest prevalence is Africa with a prevalence of 5.3 %. Genotype 1 is the most commonly encountered of the six viral genotypes. With the implementation of testing of blood products in the early 1990s, injection drug use and transmission in health and para-health care settings are now the main mechanisms of infection. HCV infection is mostly asymptomatic and diagnosed at a chronic stage by detection of anti-HCV antibodies in the blood. Nucleic acid testing confirms active HCV infection. Chronic HCV is complicated by liver cirrhosis in 20–30 % of cases. Cirrhosis is a precursor condition for hepatocellular carcinoma. The risk of hepatocellular carcinoma is increased by 17- to 20-fold in chronic HCV patients and HCV causes 20–30 % of all liver cancers worldwide. The combination of pegylated-Interferon/Ribavirin is still the standard of care for chronic HCV-infected patients who are eligible for antiviral therapy. The addition of a protease inhibitor to pegylated-Interferon/Ribavirin combination improves the rate of sustained virological response (SVR) in patients infected with HCV genotype 1. Protease inhibitors are associated with numerous side effects and alternative therapies may soon become available. HCC is the third most common cause of cancer-related death worldwide. HCV-induced HCC is expected to become the dominant cause of liver cancers as vaccination against HBV is being implemented in almost all countries. HCV-induced HCC disproportionately affects low resource countries. HCV-induced HCC mostly develops in the cirrhotic liver with transformation of regenerative nodules into dysplastic nodules and then to HCC. Death in patients with advanced HCC mostly occurs by progression to liver failure. Ultrasonographic surveillance of cirrhotics for HCC has contributed to early diagnosis of HCC. New nodules detected by ultrasonography can be confirmed with high specificity by the finding of arterial enhancement and portal venous or venous phase washout on dynamic contrast enhanced CT or MRI. The Barcelona Clinic Liver Cancer (BCLC) staging system stratifies HCC into stages of increasing severity each with its recommended treatment. The shortcoming of this staging is the heterogeneity of patients with intermediate stage disease, leading to a lack of uniformity in the treatments applied to these patients. Liver transplantation is associated with the best survival outcomes for patients with HCV-induced HCC, but graft loss can occur due to recurrence of chronic HCV in the transplanted liver. The 5-year survival of HCV-induced HCC after liver resection ranges from 40 to 70 %, but is marked by tumor recurrence rates of up to 75 % at 5 years, due to the development of de novo tumors in the residual cirrhotic liver. The best strategy to prevent HCV-induced HCC is to prevent HCV infection and to treat chronic infection at the earliest opportunity to mitigate the risk of progression to cirrhosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29 Suppl 1:74–81 [Review].

    Article  PubMed  Google Scholar 

  2. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005;42(4):962–73 [Consensus Development Conference Research Support, Non-U.S. Gov’t Review].

    Article  CAS  PubMed  Google Scholar 

  3. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5(9):558–67 [Review].

    Article  PubMed  Google Scholar 

  4. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol. 2008;48(1):148–62 [Research Support, Non-U.S. Gov’t Review].

    Article  PubMed  Google Scholar 

  5. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705–14.

    Article  PubMed  Google Scholar 

  6. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med. 1996;334(26):1685–90 [Research Support, U.S. Gov’t, P.H.S.].

    Article  CAS  PubMed  Google Scholar 

  7. Smith BD, Jorgensen C, Zibbell JE, Beckett GA. Centers for Disease Control and Prevention initiatives to prevent hepatitis C virus infection: a selective update. Clin Infect Dis. 2012;55 Suppl 1:S49–53 [Research Support, Non-U.S. Gov’t Review].

    Article  PubMed  Google Scholar 

  8. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335–74.

    Article  CAS  PubMed  Google Scholar 

  9. Antaki N, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S, et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int. 2010;30(3):342–55 [Review].

    Article  CAS  PubMed  Google Scholar 

  10. Shire AM, Sandhu DS, Kaiya JK, Oseini AM, Yang JD, Chaiteerakij R, et al. Viral hepatitis among Somali immigrants in Minnesota: association of hepatitis C with hepatocellular carcinoma. Mayo Clin Proc. 2012;87(1):17–24 [Research Support, N.I.H., Extramural].

    Article  PubMed Central  PubMed  Google Scholar 

  11. Murphy EL, Bryzman SM, Glynn SA, Ameti DI, Thomson RA, Williams AE, et al. Risk factors for hepatitis C virus infection in United States blood donors. NHLBI Retrovirus Epidemiology Donor Study (REDS). Hepatology. 2000;31(3):756–62 [Research Support, U.S. Gov’t, P.H.S.].

    Article  CAS  PubMed  Google Scholar 

  12. Centers for Disease Control and Prevention (CDC). Hepatitis C virus infection among adolescents and young adults: Massachusetts, 2002–2009. MMWR Morb Mortal Wkly Rep. 2011;60(17):537–41 [Research Support, Non-U.S. Gov’t].

    Google Scholar 

  13. Ohto H, Terazawa S, Sasaki N, Hino K, Ishiwata C, Kako M, et al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med. 1994;330(11):744–50.

    Article  CAS  PubMed  Google Scholar 

  14. Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C virus transmission? Hepatology. 2010;52(4):1497–505 [Review].

    Article  PubMed  Google Scholar 

  15. Torresi J, Johnson D, Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol. 2011;54(6):1273–85 [Review].

    Article  CAS  PubMed  Google Scholar 

  16. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000;132(4):296–305 [Consensus Development Conference, NIH Review].

    Article  CAS  PubMed  Google Scholar 

  17. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology. 2006;43(6):1303–10 [Comparative Study Research Support, Non-U.S. Gov’t].

    Article  PubMed  Google Scholar 

  18. Chevaliez S, Pawlotsky JM. Diagnosis and management of chronic viral hepatitis: antigens, antibodies and viral genomes. Best Pract Res Clin Gastroenterol. 2008;22(6):1031–48 [Review].

    Article  CAS  PubMed  Google Scholar 

  19. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47(RR-19):1–39 [Practice Guideline].

    Google Scholar 

  20. U.S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: recommendation statement. Ann Intern Med. 2004;140(6):462–4 [Practice Guideline].

    Article  Google Scholar 

  21. Ascione A, Tartaglione T, Di Costanzo GG. Natural history of chronic hepatitis C virus infection. Dig Liver Dis. 2007;39 Suppl 1:S4–7 [Review].

    Article  PubMed  Google Scholar 

  22. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology. 1996;23(6):1334–40.

    Article  CAS  PubMed  Google Scholar 

  23. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345(1):41–52 [Review].

    Article  CAS  PubMed  Google Scholar 

  24. Seeff LB. The history of the “natural history” of hepatitis C (1968-2009). Liver Int. 2009;29 Suppl 1:89–99 [Historical Article Review].

    Article  PubMed  Google Scholar 

  25. Park J-W, Sherman M, Colombo M, Roberts L, Schwartz M, Degos F, Chen P-J, Chen M, Kudo M, Johnson P, Huang B, Wagner S, Orsini LS. Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC BRIDGE study: characterization of the full study population. “A bridge to a consensus on HCC management” in The 3rd Asia-Pacific primary liver cancer expert meeting. Liver Cancer. 2012;1(2):110–40 [Abstract].

    Article  CAS  Google Scholar 

  26. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118(12):3030–44.

    Article  CAS  PubMed  Google Scholar 

  27. Hofer H, Watkins-Riedel T, Janata O, Penner E, Holzmann H, Steindl-Munda P, et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology. 2003;37(1):60–4 [Multicenter Study].

    Article  PubMed  Google Scholar 

  28. Grebely J, Matthews GV, Dore GJ. Treatment of acute HCV infection. Nat Rev Gastroenterol Hepatol. 2011;8(5):265–74 [Review].

    CAS  PubMed  Google Scholar 

  29. Vectrelis (boceprevir) capsules. Merck.

    Google Scholar 

  30. Incibek (telaprevir) film coated tablets. Vertex.pdf. May 2011.

    Google Scholar 

  31. Petta S, Craxi A. Therapeutic algorithms for chronic hepatitis C in the DAA era during the current economic crisis: whom to treat? How to treat? When to treat? BMC Infect Dis. 2012;12 Suppl 2:S3 [Review].

    Article  PubMed Central  PubMed  Google Scholar 

  32. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433–44 [Comparative Study Practice Guideline].

    Article  PubMed Central  PubMed  Google Scholar 

  33. Al Naamani K, Al Sinani S, Deschenes M. Epidemiology and treatment of hepatitis C genotypes 5 and 6. Can J Gastroenterol. 2013;27(1):e8–12.

    PubMed Central  PubMed  Google Scholar 

  34. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867–77 [Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t].

    Article  CAS  PubMed  Google Scholar 

  35. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878–87 [Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t].

    Article  CAS  PubMed  Google Scholar 

  36. Kelly C, Klenerman P, Barnes E. Interferon lambdas: the next cytokine storm. Gut. 2011;60(9):1284–93.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  37. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368(1):34–44 [Clinical Trial, Phase II Randomized Controlled Trial Research Support, Non-U.S. Gov’t].

    Article  CAS  PubMed  Google Scholar 

  38. Chatel-Chaix L, Germain MA, Gotte M, Lamarre D. Direct-acting and host-targeting HCV inhibitors: current and future directions. Current Opin Virol. 2012;2(5):588–98.

    Article  CAS  Google Scholar 

  39. Crespo G, Marino Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology. 2012;142(6):1373–83 [Research Support, Non-U.S. Gov’t Review].

    Article  PubMed  Google Scholar 

  40. Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology. 2012;55(3):742–8 [Clinical Trial, Phase II Research Support, Non-U.S. Gov’t].

    Article  CAS  PubMed  Google Scholar 

  41. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–38.

    Article  PubMed  Google Scholar 

  42. Chaiteerakij R, Yang JD, Harmsen WS, Slettedahl SW, Mettler TA, Fredericksen ZS, et al. Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology. 2013;57(2):648–55 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t].

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  43. Center MM, Jemal A. International trends in liver cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2011;20(11):2362–8 [Multicenter Study].

    Article  PubMed  Google Scholar 

  44. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.

    Article  CAS  PubMed  Google Scholar 

  45. Goodman Z, Terraciano L, Wee A. Tumours and tumour-like lesions of the liver. In: Burt A, Portmann B, Ferrel L, editors. Mac Sween’s pathology of the liver. 6th ed. Edinburgh: Churchill Livingstone Elsevier; 2012. p. 761–851.

    Chapter  Google Scholar 

  46. Sugimachi K, Tanaka S, Terashi T, Taguchi K, Rikimaru T. The mechanisms of angiogenesis in hepatocellular carcinoma: angiogenic switch during tumor progression. Surgery. 2002;131(1 Suppl):S135–41 [Review].

    Article  PubMed  Google Scholar 

  47. Federle MP, Goshima S. Use of imaging techniques to screen for hepatocellular carcinoma. In: Carr BI, editor. Hepatocellular carcinoma. 2nd ed. Philadelphia: Humana Press; 2010. p. 349–67.

    Google Scholar 

  48. Zech CJ, Bartolozzi C, Bioulac-Sage P, Chow PK, Forner A, Grazioli L, et al. Consensus report of the fifth international forum for liver MRI. AJR Am J Roentgenol. 2013;201(1):97–107.

    Article  PubMed  Google Scholar 

  49. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2 [Practice Guideline].

    Article  PubMed Central  PubMed  Google Scholar 

  50. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology. 1995;22(3):983–93 [Research Support, Non-U.S. Gov’t Review].

    Article  Google Scholar 

  51. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245–55 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Review].

    Article  PubMed  Google Scholar 

  52. Jakate S, Yabes A, Giusto D, Naini B, Lassman C, Yeh MM, et al. Diffuse cirrhosis-like hepatocellular carcinoma: a clinically and radiographically undetected variant mimicking cirrhosis. Am J Surg Pathol. 2010;34(7):935–41 [Multicenter Study].

    Article  PubMed  Google Scholar 

  53. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907–17 [Research Support, Non-U.S. Gov’t Review].

    Article  PubMed  Google Scholar 

  54. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4(2):439–74.

    Article  PubMed Central  PubMed  Google Scholar 

  55. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–9 [Research Support, Non-U.S. Gov’t].

    Article  CAS  PubMed  Google Scholar 

  56. Takuma Y, Nouso K, Makino Y, Gotoh T, Toshikuni N, Morimoto Y, et al. Outcomes after curative treatment for cryptogenic cirrhosis-associated hepatocellular carcinoma satisfying the Milan criteria. J Gastroenterol Hepatol. 2011;26(9):1417–24 [Comparative Study].

    PubMed  Google Scholar 

  57. Freeman RB, Wiesner RH, Edwards E, Harper A, Merion R, Wolfe R. Results of the first year of the new liver allocation plan. Liver Transpl. 2004;10(1):7–15.

    Article  PubMed  Google Scholar 

  58. Sugimachi K, Kinjo N, Ikebe M, Yamashita N, Kajiwara E, Mimori K, et al. Significance of hepatic resection for hepatocellular carcinoma with sustained virological response to interferon therapy for chronic hepatitis C. Hepatol Res. 2013;43(6):605–9.

    Article  CAS  PubMed  Google Scholar 

  59. Tsunedomi R, Iizuka N, Yoshimura K, Iida M, Tsutsui M, Hashimoto N, et al. ABCB6 mRNA and DNA methylation levels serve as useful biomarkers for prediction of early intrahepatic recurrence of hepatitis C virus-related hepatocellular carcinoma. Int J Oncol. 2013;42(5):1551–9 [Research Support, Non-U.S. Gov’t].

    CAS  PubMed Central  PubMed  Google Scholar 

  60. Barbara L, Benzi G, Gaiani S, Fusconi F, Zironi G, Siringo S, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology. 1992;16(1):132–7.

    Article  CAS  PubMed  Google Scholar 

  61. Chirica M, Tranchart H, Tan V, Faron M, Balladur P, Paye F. Infection with hepatitis C virus is an adverse prognostic factor after liver resection for early-stage hepatocellular carcinoma: implications for the management of hepatocellular carcinoma eligible for liver transplantation. Ann Surg Oncol. 2013;20(7):2405–12.

    Article  PubMed  Google Scholar 

  62. Huo TI, Lin HC, Hsia CY, Wu JC, Lee PC, Chi CW, et al. The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey. Am J Gastroenterol. 2007;102(9):1920–30 [Research Support, Non-U.S. Gov’t].

    Article  PubMed  Google Scholar 

  63. Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology. 2008;47(1):82–9 [Comparative Study Multicenter Study].

    Article  PubMed  Google Scholar 

  64. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S179–88 [Research Support, Non-U.S. Gov’t Review].

    Article  CAS  PubMed  Google Scholar 

  65. Luna LE, Kwo PY, Roberts LR, Mettler TA, Gansen DN, Andrews JC, et al. Liver transplantation after radioembolization in a patient with unresectable HCC. Nat Rev Gastroenterol Hepatol. 2009;6(11):679–83 [Case Reports Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Review].

    Article  PubMed  Google Scholar 

  66. Nault JC, De Reynies A, Villanueva A, Calderaro J, Rebouissou S, Couchy G, et al. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology. 2013;145(1):176–87.

    Article  CAS  PubMed  Google Scholar 

  67. Bartosch B, Thimme R, Blum HE, Zoulim F. Hepatitis C virus-induced hepatocarcinogenesis. J Hepatol. 2009;51(4):810–20 [Review].

    Article  CAS  PubMed  Google Scholar 

  68. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–76 [Review].

    Article  CAS  PubMed  Google Scholar 

  69. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 Suppl 1):S35–50 [Review].

    Article  PubMed  Google Scholar 

  70. Sun CA, Wu DM, Lin CC, Lu SN, You SL, Wang LY, et al. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol. 2003;157(8):674–82 [Research Support, Non-U.S. Gov’t].

    Article  PubMed  Google Scholar 

  71. Colombo M, Donato MF. Prevention of hepatocellular carcinoma. Semin Liver Dis. 2005;25(2):155–61 [Review].

    Article  PubMed  Google Scholar 

  72. Somasundaram A, Venkataraman J. Antiviral treatment for cirrhosis due to hepatitis C: a review. Singapore Med J. 2012;53(4):231–5 [Review].

    PubMed  Google Scholar 

  73. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer. 1997;79(8):1494–500 [Comparative Study].

    Article  CAS  PubMed  Google Scholar 

  74. Morgan TR. Chemoprevention of hepatocellular carcinoma in chronic hepatitis C. Recent Results Cancer Res. 2011;188:85–99 [Review].

    Article  CAS  PubMed  Google Scholar 

  75. Manns MP, Wedemeyer H, Singer A, Khomutjanskaja N, Dienes HP, Roskams T, et al. Glycyrrhizin in patients who failed previous interferon alpha-based therapies: biochemical and histological effects after 52 weeks. J Viral Hepat. 2012;19(8):537–46 [Clinical Trial, Phase III Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t].

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  76. Davila JA, Henderson L, Kramer JR, Kanwal F, Richardson PA, Duan Z, et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med. 2011;154(2):85–93 [Multicenter Study Research Support, N.I.H., Extramural Research Support, U.S. Gov’t, Non-P.H.S.].

    Article  PubMed  Google Scholar 

  77. El-Serag HB, Kramer JR, Chen GJ, Duan Z, Richardson PA, Davila JA. Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut. 2011;60(7):992–7 [Evaluation Studies Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S.].

    Article  CAS  PubMed  Google Scholar 

  78. Tong MJ, Chavalitdhamrong D, Lu DS, Raman SS, Gomes A, Duffy JP, et al. Survival in Asian Americans after treatments for hepatocellular carcinoma: a seven-year experience at UCLA. J Clin Gastroenterol. 2010;44(3):e63–70.

    Article  PubMed  Google Scholar 

  79. Kohli V, Singhal A, Elliott L, Jalil S. Antiviral therapy for recurrent hepatitis C reduces recurrence of hepatocellular carcinoma following liver transplantation. Transpl Int. 2012;25(2):192–200.

    Article  CAS  PubMed  Google Scholar 

  80. Zhong JH, Li H, Li LQ, You XM, Zhang Y, Zhao YN, et al. Adjuvant therapy options following curative treatment of hepatocellular carcinoma: a systematic review of randomized trials. Eur J Surg Oncol. 2012;38(4):286–95 [Research Support, Non-U.S. Gov’t Review].

    Article  PubMed  Google Scholar 

  81. Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med. 2003;138(4):299–306 [Clinical Trial Randomized Controlled Trial].

    Article  PubMed  Google Scholar 

  82. Kimer N, Dahl EK, Gluud LL, Krag A. Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2012;2(5).

    Google Scholar 

  83. Miyatake H, Kobayashi Y, Iwasaki Y, Nakamura S, Ohnishi H, Kuwaki K, et al. Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma. Dig Dis Sci. 2012;57(4):1092–101.

    Article  CAS  PubMed  Google Scholar 

  84. Takeyasu M, Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, et al. Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma. J Med Virol. 2012;84(8):1199–207 [Research Support, Non-U.S. Gov’t].

    Article  CAS  PubMed  Google Scholar 

  85. Shimizu M, Shirakami Y, Imai K, Takai K, Moriwaki H. Acyclic retinoid in chemoprevention of hepatocellular carcinoma: Targeting phosphorylated retinoid X receptor-alpha for prevention of liver carcinogenesis. J Carcinog. 2012;11:11.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  86. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med. 1996;334(24):1561–7 [Clinical Trial Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t].

    Article  CAS  PubMed  Google Scholar 

  87. Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med. 1999;340(13):1046–7 [Comment Letter].

    Article  CAS  PubMed  Google Scholar 

  88. Okita T, Matsui O, Kumada H, Tanaka K, Kaneko S, Morikawa H, et al. Effect of peritonoin on recurrence of hepatocellular carcinoma (HCC): results of phase II/III randomized placebo-controlled trial. J Clin Oncol. 2010;28(Suppl 15):abstr 4024.

    Google Scholar 

  89. Okusaka T, Makuuchi M, Matsui O, Kumada H, Tanaka K, Kaneko S, et al. Clinical benefit of peritonoin for the suppression of hepatocellular carcinoma (HCC) recurrence in patients with Child-Pugh grade A (CP-A) and small tumor: a subgroup analysis in phase II/III randomized placebo-controlled trial. J Clin Oncol. 2011;29(Suppl 4):abstr 165.

    Google Scholar 

  90. Yoshida H, Shiratori Y, Kudo M, Shiina S, Mizuta T, Kojiro M, et al. Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology. 2011;54(2):532–40 [Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t].

    Article  CAS  PubMed  Google Scholar 

  91. Zhang H, Ozaki I, Hamajima H, Iwane S, Takahashi H, Kawaguchi Y, et al. Vitamin K2 augments 5-fluorouracil-induced growth inhibition of human hepatocellular carcinoma cells by inhibiting NF-kappaB activation. Oncol Rep. 2011;25(1):159–66 [Research Support, Non-U.S. Gov’t].

    CAS  PubMed  Google Scholar 

  92. Boucher E, Corbinais S, Rolland Y, Bourguet P, Guyader D, Boudjema K, et al. Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology. 2003;38(5):1237–41.

    Article  CAS  PubMed  Google Scholar 

  93. Chung AY, Ooi LL, Machin D, Tan SB, Goh BK, Wong JS, et al. Adjuvant hepatic intra-arterial iodine-131-lipiodol following curative resection of hepatocellular carcinoma: a prospective randomized trial. World J Surg. 2013;37(6):1356–61 [Research Support, Non-U.S. Gov’t].

    Article  CAS  PubMed  Google Scholar 

  94. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 2000;356(9232):802–7 [Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov’t].

    Article  CAS  PubMed  Google Scholar 

  95. WHO International Travel and Health. Global prevalence of hepatitis A, B and C. http://www.who.int/docstore/wer/pdf/2002/wer7706.pdf (2002).

  96. Wong T, Lee SS. Hepatitis C: a review for primary care physicians. Can Med Assoc J. 2006;174(5):649–59.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gastroenterology Basic Research, Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN, 55905, USA

    Albert Ndzengue M.D., M.Sc.

  2. Department of Internal Medicine, Gyeongsang National University Hospital, 79 Gangnam-Ro, Jinju, Gyeongsangnam-do, 660-702, South Korea

    Tae Hyo Kim M.D., Ph.D.

  3. Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    Abdirashid M. Shire Ph.D.

  4. Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Mayo Clinic Cancer Center, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    Lewis R. Roberts M.B., Ch.B., Ph.D.

Authors
  1. Albert Ndzengue M.D., M.Sc.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tae Hyo Kim M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Abdirashid M. Shire Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lewis R. Roberts M.B., Ch.B., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Albert Ndzengue M.D., M.Sc. .

Editor information

Editors and Affiliations

  1. Pathology and Laboratory Medicine, Yale University School of Medicine, New Haven, Connecticut, USA

    S. David Hudnall

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Ndzengue, A., Kim, T.H., Shire, A.M., Roberts, L.R. (2014). Hepatitis C Virus: Epidemiology and Clinical Features of Related Cancer. In: Hudnall, S. (eds) Viruses and Human Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0870-7_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-0870-7_5

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-0869-1

  • Online ISBN: 978-1-4939-0870-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation